OC-0088 Margin calculation for multiple metastases in single-isocenter lung SBRT

2021 ◽  
Vol 161 ◽  
pp. S62-S63
Author(s):  
J. van Timmeren ◽  
M. Hoogeman ◽  
S. Ehrbar ◽  
M. Mayinger ◽  
N. Andratschke ◽  
...  
2021 ◽  
Vol 86 ◽  
pp. 82-90
Author(s):  
José Alejandro Rojas-López ◽  
Rogelio Manuel Díaz Moreno ◽  
Carlos Daniel Venencia

2020 ◽  
Author(s):  
Raphael Bodensohn ◽  
Anna-Lena Kaempfel ◽  
Daniel Felix Fleischmann ◽  
Indrawati Hadi ◽  
Jan Hofmaier ◽  
...  

Abstract Background Single-isocenter dynamic conformal arc (SIDCA) therapy is an efficient way of delivering stereotactic radiosurgery (SRS) to multiple metastases simultaneously. This study reports on the safety and feasibility of SRS with SIDCA for patients with multiple brain metastases.Methods All patients who received SRS with this technique between November 2017 and June 2019 within a prospective registry trial, were included. The patients were irradiated using a VersaHD® linear accelerator (LINAC) from Elekta (Stockholm, Sweden). Follow-up was performed every three months, including a clinical and radiological examination with cranial magnetic resonance imaging (MRI). The data were analyzed using descriptive statistics and the Kaplan-Meier method.Results 65 patients with 254 lesions (range 2–12) were included in this analysis. Median beam on time was 23 minutes. The median follow-up at the time of analysis was 13 months (95% CI 11.1–14.9). Median overall survival and median progression-free survival was 15 months (95% CI 7.7–22.3) and 18 months (95% CI 11.1–24.9), respectively. Intracranial and local control after 6 months was 73.0% and 97.5%, respectively. During follow-up, CTCAE grade 1 adverse effects (AE) were experienced by 29 (44.6%) patients (18 of them therapy-related (27.7%)), CTCAE grade 2 AEs by 4 (6.2%) patients (one of them therapy-related (1.5%)) and CTCAE grade 3 by 3 patients (4.6%) (none of them therapy-related). 2 lesions (0.8%) in 2 patients (3.1%) were proven as radiation necrosis. Conclusions Simultaneous SRS using SIDCA seems to be a feasible and safe treatment for patients with multiple metastases.


2019 ◽  
Vol 20 (5) ◽  
pp. 55-63 ◽  
Author(s):  
Damodar Pokhrel ◽  
Lana Sanford ◽  
Matthew Halfman ◽  
Janelle Molloy

2019 ◽  
Vol 20 (8) ◽  
pp. 21-28 ◽  
Author(s):  
Kang‐Hyun Ahn ◽  
Kamil M. Yenice ◽  
Matthew Koshy ◽  
Konstantin V. Slavin ◽  
Bulent Aydogan

Author(s):  
C. Velten ◽  
D.K. Mynampati ◽  
M.K. Garg ◽  
R. Kabarriti ◽  
A. Basavatia ◽  
...  

Author(s):  
Raphael Bodensohn ◽  
Anna-Lena Kaempfel ◽  
Daniel Felix Fleischmann ◽  
Indrawati Hadi ◽  
Jan Hofmaier ◽  
...  

Abstract Background Single-isocenter dynamic conformal arc (SIDCA) therapy is a technically efficient way of delivering stereotactic radiosurgery (SRS) to multiple metastases simultaneously. This study reports on the safety and feasibility of linear accelerator (LINAC) based SRS with SIDCA for patients with multiple brain metastases. Methods All patients who received SRS with this technique between November 2017 and June 2019 within a prospective registry trial were included. The patients were irradiated with a dedicated planning tool for multiple brain metastases using a LINAC with a 5 mm multileaf collimator. Follow-up was performed every 3 months, including clinical and radiological examination with cranial magnetic resonance imaging (MRI). These early data were analyzed using descriptive statistics and the Kaplan–Meier method. Results A total of 65 patients with 254 lesions (range 2–12) were included in this analysis. Median beam-on time was 23 min. The median follow-up at the time of analysis was 13 months (95% CI 11.1–14.9). Median overall survival and median intracranial progression-free survival was 15 months (95% CI 7.7–22.3) and 7 months (95% CI 3.9–10.0), respectively. Intracranial and local control after 1 year was 64.6 and 97.5%, respectively. During follow-up, CTCAE grade I adverse effects (AE) were experienced by 29 patients (44.6%; 18 of them therapy related, 27.7%), CTCAE grade II AEs by four patients (6.2%; one of them therapy related, 1.5%), and CTCAE grade III by three patients (4.6%; none of them therapy related). Two lesions (0.8%) in two patients (3.1%) were histopathologically proven to be radiation necrosis. Conclusion Simultaneous SRS using SIDCA seems to be a feasible and safe treatment for patients with multiple brain metastases.


2014 ◽  
Vol 90 (1) ◽  
pp. S910-S911 ◽  
Author(s):  
M. Gulam ◽  
A. Gopal ◽  
N. Wen ◽  
J. Gordon ◽  
K.J. Levin ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document